Janssen Pharmaceuticals Inc.’s price concessions in the 340B outpatient drug discount program rose from $2bn in 2016 to $6.4bn in 2021, driven by the rapid growth in contract pharmacy participation in the program over the past five years, according to the company’s recently-released US Transparency Report for 2021.
From 2020 to 2021 alone, 340B discounts increased by more than $1bn, after reaching $5.3bn in 2020, Janssen reported. The...







